|
Sign In to gain access to subscriptions and/or personal tools.
|
Clinical and Applied Thrombosis/Hemostasis, Vol. 12, No. 4,
485-488 (2006)
DOI: 10.1177/1076029606293438
Spectrum of Bleeding in Acquired Factor V Inhibitor: A Summary of 33 Cases
Viroj Wiwanitkit, MD
Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Coagulation factor V (FV) is an essential component of the prothrombinase complex, which activates the zymogen prothrombin to thrombin. Acquired FV inhibitor is rare and clinical symptoms are quite variable. The aim of this study was to summarize the spectrum of the bleeding presentation of acquired FV deficiency and characterize the underlying causes of the clinical symptoms. This study was designed as a descriptive retrospective and 30 case reports were included for further analysis. At least 33 cases of acquired FV inhibitor were investigated. Most patients have a presentation of bleeding and most of those are from hematuria and bleeding at surgical sites. Seven cases of asymptomatic acquired FV inhibitor were also detected. A total of 39.4% (19 of 33) of those cases with acquired FV inhibitor have an unknown cause. For those with known etiologies, chemical and drug-induced causes are the most common (30.8%).
Key Words: Factor V • Bleeding • Presentation
References
- Ajzner E, Balogh I, Haramura G, et al. Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding. J Thromb Haemost 2003; 1: 943-943.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Okoshi Y, Akiyama H, Inoue T, et al. A long-lasting idiopathic factor V inhibitor. Rinsho Ketsueki 2003; 44: 14-14.[Medline]
[Order article via Infotrieve]
- Feinstein DI. Acquired inhibitors of factor V. Thromb Haemost 1978; 39: 663-663.[ISI][Medline]
[Order article via Infotrieve]
- Lu L, Liu Y, Wei J, et al. Acquired inhibitor of factor V: First report in China and literature review. Haemophilia 2004; 10: 661-661.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- de Raucourt E, Barbier C, Sinda P, et al. High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors. Am J Hematol 2003; 74: 187-187.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Hasegawa M, Tanaka T, Kii T, et al. Acquired inhibitor against coagulation factor V with severe hematuria. Rinsho Ketsueki 2003; 44: 933-933.[Medline]
[Order article via Infotrieve]
- Caers J, Reekmans A, Jochmans K, et al. Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer. Endoscopy 2003; 35: 542-542.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Takahashi H, Fuse I, Abe T, et al. Acquired factor V inhibitor complicated by Hashimoto’s thyroditis, primary biliary cirrhosis and membranous nephropathy. Blood Coagul Fibrinolysis 2003; 14: 87-87.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Kyriakou DS, Alexandrakis MG, Passam FH, et al. Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. Eur J Gastroenterol Hepatol 2002; 14: 1383-1383.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Bayani N, Rugina M, Haddad-Vergnes L, Lelong F. High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors. Am J Hematol 2002; 71: 33-33.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Emori Y, Sakugawa M, Niiya K, et al. Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. Blood Coagul Fibrinolysis 2002; 13: 555-555.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Schleinitz N, Veit V, Chouquet D, et al. Acquired factor V inhibitor: Etiology, bleeding risk and therapeutic management with regard to three cases. Rev Med Interne 2001; 22: 1119-1119.[ISI][Medline]
[Order article via Infotrieve]
- Kajitani M, Ozdemir A, Aguinaga M, et al. Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg 2000; 15: 378-378.[ISI][Medline]
[Order article via Infotrieve]
- Yamane T, Hino M, Ota K, et al. Clinical cases of acquired coagulation inhibitors. Rinsho Byori 2000; 48: 1093-1093.[Medline]
[Order article via Infotrieve]
- Shastri KA, Ho C, Logue G. An acquired factor V inhibitor: Clinical and laboratory features. J Med 1999; 30: 357-357.[CrossRef][Medline]
[Order article via Infotrieve]
- Zumberg MS, Waples JM, Kao KJ, Lottenberg R. Management of a patient with a mechanical aortic valve and antibodies to both thrombin and factor V after repeat exposure to fibrin sealant. Am J Hematol 2000; 64: 59-59.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Tarantino MD, Ross MP, Daniels TM, Nichols WL. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin. J Pediatr Hematol Oncol 1997; 19: 226-226.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Brickner LA, Scannell KA, Sahud MA. Acquired factor V inhibitor in a patient with acquired human immunodeficiency syndrome. Am J Hematol 1996; 52: 332-332.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Fu YX, Kaufman R, Rudolph AE, et al. Multimodality therapy of an acquired factor V inhibitor. Am J Hematol 1996; 51: 315-315.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- George S, Nagabhushana MS, Cyran EM. Coagulopathy due to an acquired factor V inhibitor and subsequently thrombosis. Am J Hematol 1995; 49: 98-98.[ISI][Medline]
[Order article via Infotrieve]
- Denis A, Baudeau C, Verdy E, et al. Acquired circulating anticoagulant with anti-factor V activity in AIDS: First case report. Nouv Rev Fr Hematol 1995; 37: 165-165.[Medline]
[Order article via Infotrieve]
- Leclerc J, Charre S, Tournoys A, et al. Postoperative disorders of hemostasis caused by antifactor V circulating anticoagulant. Ann Fr Anesth Reanim 1995; 14: 303-303.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Israels SJ, Israels ED. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. Am J Pediatr Hematol Oncol 1994; 16: 249-249.[ISI][Medline]
[Order article via Infotrieve]
- Coots MC, Muhleman AF, Glueck HI. Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol 1978; 4: 193-193.[ISI][Medline]
[Order article via Infotrieve]
- Banninger H, Hardegger T, Tobler A, et al. Fibrin glue in surgery: Frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 1993; 85: 528-528.[ISI][Medline]
[Order article via Infotrieve]
- Buclin T, Schmidt PM, Hauert J, et al. Acquired factor V inhibitor treated with intravenous immunoglobulins. Schweiz Med Wochenschr 1992; 122: 1968-1968.[ISI][Medline]
[Order article via Infotrieve]
- Grigg AP, Dauer R, Thurlow PJ. Bleeding due to an acquired inhibitor of platelet associated factor V. Aust N Z J Med 1989; 9: 310-310.
- Nesheim ME, Nichols WL, Cole TL, et al. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 1986; 77: 405-405.[ISI][Medline]
[Order article via Infotrieve]
- Chong LL, Wong YC. A case of factor V inhibitor. Am J Hematol 1985; 19: 395-395.[ISI][Medline]
[Order article via Infotrieve]
- Vickars LM, Coupland RW, Naiman SC. The response of an acquired Factor V inhibitor to activated Factor IX concentrate. Transfusion 1985; 25: 51-51.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Knobl P, Lechner K. Acquired factor V inhibitors. Baillieres Clin Haematol 1998; 11: 305-305.[ISI][Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. Zhang, M. Spreafico, C. Zheng, A. Yang, P. Platzer, M. U. Callaghan, Z. Avci, N. Ozbek, J. Mahlangu, T. Haw, et al.
Genotype-phenotype correlation in combined deficiency of factor V and factor VIII
Blood,
June 15, 2008;
111(12):
5592 - 5600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
